These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 20686912)

  • 1. Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.
    Fröhlich E
    Cell Mol Life Sci; 2010 Dec; 67(23):3947-60. PubMed ID: 20686912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteases in cutaneous melanoma.
    Ferrier CM; van Muijen GN; Ruiter DJ
    Ann Med; 1998 Oct; 30(5):431-42. PubMed ID: 9814829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathology of malignant melanoma, including new markers and techniques in diagnosis and prognosis.
    De Wit PE; Van Muijen GN; De Waal RM; Ruiter DJ
    Curr Opin Oncol; 1996 Mar; 8(2):143-51. PubMed ID: 8727307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanocytic schwannoma of the cutaneous and subcutaneous tissues: three cases and a review of the literature.
    Kaehler KC; Russo PA; Katenkamp D; Kreusch T; Neuber K; Schwarz T; Hauschild A
    Melanoma Res; 2008 Dec; 18(6):438-42. PubMed ID: 19011514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma.
    Vuoristo MS; Kellokumpu-Lehtinen P; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E; Laine S
    Acta Oncol; 2000; 39(7):877-9. PubMed ID: 11145448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
    Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
    J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of melanocytic tumour progression.
    Ruiter DJ; van Muijen GN
    J Pathol; 1998 Dec; 186(4):340-2. PubMed ID: 10209480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma.
    Ren S; Smith MJ; Louro ID; McKie-Bell P; Bani MR; Wagner M; Zochodne B; Redden DT; Grizzle WE; Wang Nd; Smith DI; Herbst RA; Bardenheuer W; Opalka B; Schütte J; Trent JM; Ben-David Y; Ruppert JM
    Oncogene; 2000 Mar; 19(11):1419-27. PubMed ID: 10723133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of proteolytic enzymes in skin neoplasm progression and development of metastasis].
    Kozłowski L; Wojtukiewicz MZ
    Postepy Hig Med Dosw; 1999; 53(6):841-54. PubMed ID: 10737043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous melanocytic dysplasia and malignant melanoma. A critical review.
    Kwittken J
    J Med; 1991; 22(1):1-16. PubMed ID: 2072047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of cyclooxygenase-2 (COX-2) in oral nevi and melanoma.
    de Souza do Nascimento J; Carlos R; Delgado-Azañero W; Mosqueda Taylor A; de Almeida OP; Romañach MJ; de Andrade BA
    J Oral Pathol Med; 2016 Jul; 45(6):440-3. PubMed ID: 26608958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
    Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions.
    Dundr P; Simon K; Němejcová K; Bártů M; Tichá I; Michálková R; Jakša R; Věcková Z; Kodet O
    Melanoma Res; 2019 Apr; 29(2):157-162. PubMed ID: 30422880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-kit expression of melanocytic neoplasm and association with clinicopathological parameters and anatomic locations in Chinese people.
    Lin YC; Chang YM; Ho JY; Lin HC; Tsai YM; Chiang CP; Wang WM; Gao HW
    Am J Dermatopathol; 2013 Jul; 35(5):569-75. PubMed ID: 23221472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alarmins in cutaneous malignant melanoma: An updated overview of emerging evidence on their pathogenetic, diagnostic, prognostic, and therapeutic role.
    Papa V; Li Pomi F; Borgia F; Vaccaro M; Pioggia G; Gangemi S
    J Dermatol; 2024 Jul; 51(7):927-938. PubMed ID: 38775220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of monoacylglycerol lipase as a marker of tumour invasion and progression in malignant melanoma.
    Baba Y; Funakoshi T; Mori M; Emoto K; Masugi Y; Ekmekcioglu S; Amagai M; Tanese K
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2038-2045. PubMed ID: 28681540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.
    Glaessl A; Bosserhoff AK; Buettner R; Hohenleutner U; Landthaler M; Stolz W
    Arch Dermatol Res; 1999; 291(2-3):81-7. PubMed ID: 10195394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of two morphologic parameters concerning tumor-stroma interaction in benign and malignant melanocytic skin lesions.
    Fink-Puches R; Smolle J; Hofmann-Wellenhof R; Kerl H
    Am J Dermatopathol; 1998 Oct; 20(5):468-72. PubMed ID: 9790107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.